Rybelsus 3 mg (Semaglutide 3 mg) (Per Box)

What is Rybelsus 3 mg?

Rybelsus® 3 mg is the starting dose of oral semaglutide, a once-daily GLP-1 receptor agonist used to help adults with type 2 diabetes control their blood sugar levels. It mimics the natural gut hormone GLP-1, enhancing insulin secretion and reducing blood sugar in a glucose-dependent manner. While this dose is not intended for long-term glycemic control, it plays a crucial role in allowing the body to gradually adjust to semaglutide before increasing to therapeutic doses (7 mg or 14 mg).

Approved Uses

Rybelsus 3 mg is indicated for:

• Initiating treatment in type 2 diabetes mellitus
  It is used for the first 30 days to help the body tolerate semaglutide, minimizing gastrointestinal side effects before progressing to higher doses for full therapeutic effect.

• Not used for glycemic maintenance or weight loss
  This dose alone does not offer significant blood sugar or weight reduction but is an essential first step in titration.

How It Works

Semaglutide acts on GLP-1 receptors in the pancreas, brain, and gut to:

• Stimulate insulin release only when glucose levels are high

• Suppress glucagon secretion, lowering hepatic glucose output

• Slow gastric emptying to reduce post-meal glucose spikes

• Decrease appetite and promote satiety

Although the 3 mg dose has limited metabolic impact, it activates these pathways at a low level to reduce side effects as the dose increases.

Clinical Benefits

• Smooth introduction to therapy

• Minimizes nausea and GI intolerance when transitioning to higher doses

• Forms part of a stepwise titration strategy for long-term blood sugar and weight management

Drug Interactions

• May affect absorption of other oral medications by slowing gastric emptying

• Use caution when co-administered with:

  • Insulin or sulfonylureas (risk of low blood sugar)

  • Drugs requiring rapid absorption — take them at a separate time

• Semaglutide has minimal CYP450 interaction (peptide-based clearance)

Food Interactions

• Must be taken on an empty stomach with plain water only

• Wait at least 30 minutes before eating, drinking, or taking other medications

• Grapefruit and high-fat meals may worsen nausea or delay absorption in sensitive users

Monitoring

Patients initiating Rybelsus should be monitored for:

• Blood glucose levels and HbA1c

• Gastrointestinal tolerance (nausea, bloating, etc.)

• Readiness to increase to 7 mg after 30 days of initiation

• Body weight and dietary habits over time (for future weight management)

Precautions

• Not for use in type 1 diabetes or diabetic ketoacidosis

• Contraindicated in patients with a personal/family history of MTC or MEN2 syndrome

• Not recommended during pregnancy or breastfeeding

• Use with caution in individuals with gastrointestinal disorders, pancreatitis history, or severe renal impairment